Abstract: The epidermal growth factor receptor (EGFR) is overexpressed in as many as 77% of colorectal cancer (CRC) cases. The EGFR is known to be involved in carcinogenetic processes such as cell proliferation, apoptosis, angiogenesis, cell motility, and metastasis. Preclinical and clinical studies have shown that targeting EGFR is a valid strategy for anticancer therapy. Currently, 2 classes of anti-EGFR agents are in phase II/III clinical development: monoclonal antibodies and tyrosine kinase (TK) inhibitors. The most established monoclonal antibody is cetuximab, the only EGFR inhibitor that is currently approved for use in patients with metastatic CRC. Several clinical studies of cetuximab, as a single agent or in combination with irinotecan, have shown promising efficacy in patients with metastatic CRC. READ MORE
published April 5th, 2005
Fragrance is one of the key decisions to be made when creating any skincare products, and our team of doctors, formulators and skincare experts created our formulas with very explicit instructions to design the products without any unnecessary fragrances, dyes, or ingredients.
However, the key word here is “unnecessary”.